AIRWAY PERFUSION ASSISTED LIQUID VENTILATOR

气道灌注辅助液体呼吸机

• 批准号: 6404857
• 负责人: JAMES Courtney PARKER
• 金额: $ 24.98万
• 依托单位: MALLARD MEDICAL CO., INC.
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-04-01 至 2003-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6404857
• 关键词: cystic fibrosis; fluid; fluosol; histology; laboratory rabbit; perfusion; respirators; respiratory airway clearance; respiratory airway volume; respiratory disorder chemotherapy; respiratory insufficiency /failure; swine; technology /technique development

DESCRIPTION (provided by applicant): We have developed and patented (U.S. Pat No. 5,706,830) a new type of closed circuit perfluorocarbon (PFC) liquid ventilator with enhanced capabilities for gas exchange and exudates clearance from the lungs. This system has potential application to rescue of patients in acute respiratory failure and treatment of cystic fibrosis. The system employs a continuous isovolumetric perfusion (bias flow) of oxygenated PFC through one lumen of a double lumen endotracheal catheter that is superimposed on tidal liquid ventilation (liv). Phase I studies in newborn piglets indicate that bias flow significantly improved blood gases and increased the clearance of a five percent albumin solution from the lung by over 3-fold. During Phase II we propose to finalize the prototype design and control system software for ventilatory parameters and a feedback control of lung liquid volume based on measurements of end-expiratory stop-flow pressures. High performance pulseless pumps, an oxygenator and vapor recovery system will be included as well as protective algorithms and relief valves to limit airway pressure excursions. Phase II experimental studies in piglets and rabbits will examine novel applications of TLV with bias flow for sustaining arterial blood gases during oleic acid lung injury, increasing the clearance rate of five percent albumin solution and mucus-like gels from the lung, and enhancing the homogeneity of gene expression for a reporter gene introduced during TLV. We will also apply for an Investigational Device Exemption (IDE) from the Food and Drug Administration during Phase II to distribute ventilator prototypes to research institutions. PROPOSED COMMERCIAL APPLICATION: This liquid ventilator will be used in infant and adult intensive care units to treat end-stage respiratory failure as a lower cost alternative to extracorporeal oxygenation. Other applications include continuous intrapulmonary administration of drugs and anesthetics and clearance of material from the lungs.

描述（由申请人提供）：我们已开发和专利（美国PAT No. 5,706,830）一种新型的闭路全氟化合物（PFC）液体 呼吸机具有增强的气体交换功能并散发出通气 从肺部。该系统有潜在的应用于营救患者 急性呼吸衰竭和囊性纤维化的治疗。该系统采用 通过一个含氧PFC的连续等量灌注（偏置流） 双管子内气管导管的腔，该导管叠加在潮汐上 液体通风（LIV）。新生小猪的第一阶段研究表明偏见 流量显着改善了血液，并增加了五个 从肺部蛋白溶液的百分比溶解度高3倍。在第二阶段我们 建议最终确定原型设计和控制系统软件 基于肺液体体积的通气参数和反馈控制 最终呼吸停止压力的测量。高性能无脉冲 泵，氧合和蒸气恢复系统将包括在内 保护性算法和浮雕阀，以限制气道压力偏移。 仔猪和兔子的II期实验研究将检查新颖 TLV与偏置流的应用，以维持动脉血气 油酸肺损伤，增加了5％白蛋白的清除率 肺部的溶液和粘液状凝胶，并增强 TLV期间引入的报告基因的基因表达。我们还将申请 用于避免食品和药物的研究装置豁免（IDE） 在第二阶段的行政 机构。 拟议的商业应用： 该液态呼吸机将用于婴儿和成人重症监护病房，以将终末期呼吸衰竭视为体外氧合的较低成本替代品。 其他应用包括连续肺内药物和麻醉药以及肺部的材料清除。